Torello Lotti, Tania Rivkina and Miroslava Kadurina
Vitiligo is a dermatologic pigmentary disorder triggered by melanocytes’ loss and sustained by a deep immune imbalance which induce chronic inflammation and excessive oxidative stress phenomena at skin level. Current therapies are mainly symptomatic and designed in order to inhibit the inflammatory mediators at vitiligo patches level. To restore the correct immune balance between Th1/Th17 and Th2/Treg response and concomitantly rebalancing the inflammatory response represents an innovative and effective approach for Vitiligo treatment; Low Dose Medicine theories and the availability of specific low dose SKA interleukins, antibodies and growth factors allows researchers and clinicians to act simultaneously against all the main etiologic causes of vitiligo and makes possible to design new therapeutic approaches for vitiligo.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 